Tenvie Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 48

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $200M

  • Investors
  • 4

Tenvie General Information

Description

Developer of small-molecule therapeutics intended to treat neurological and peripheral diseases. The company develops precision-engineered, brain-penetrant and peripherally restricted small-molecule therapies targeting neuroinflammation, metabolic dysfunction, and lysosomal function, enabling patients with neurological, cardiometabolic, and ophthalmic diseases to access novel treatment options.

Contact Information

Website
www.tenvie.com
Formerly Known As
NICO Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1400 Sierra Point Parkway
  • Suite 300
  • Brisbane, CA 94005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1400 Sierra Point Parkway
  • Suite 300
  • Brisbane, CA 94005
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tenvie Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 18-Dec-2024 $200M Completed Clinical Trials - General
To view Tenvie’s complete valuation and funding history, request access »

Tenvie Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Tenvie’s complete cap table history, request access »

Tenvie Patents

Tenvie Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213354-A1 Compounds, compositions, and methods Pending 02-Apr-2025
WO-2026136648-A1 Modulators of nlr family pyrin domain containing 3 and methods associated therewith Pending 19-Dec-2024
WO-2025260014-A1 Compounds, compositions, and methods Pending 14-Jun-2024
WO-2025213088-A1 Compounds, compositions, and methods Pending 05-Apr-2024
EP-4794693-A1 Compounds, compositions, and methods Pending 20-Oct-2023 C07D401/12
To view Tenvie’s complete patent history, request access »

Tenvie Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tenvie Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
F-Prime Venture Capital Minority
Mubadala Capital Asset Manager Minority
To view Tenvie’s complete investors history, request access »

Tenvie FAQs

  • When was Tenvie founded?

    Tenvie was founded in 2024.

  • Where is Tenvie headquartered?

    Tenvie is headquartered in Brisbane, CA.

  • What is the size of Tenvie?

    Tenvie has 48 total employees.

  • What industry is Tenvie in?

    Tenvie’s primary industry is Drug Discovery.

  • Is Tenvie a private or public company?

    Tenvie is a Private company.

  • What is the current valuation of Tenvie?

    The current valuation of Tenvie is .

  • What is Tenvie’s current revenue?

    The current revenue for Tenvie is .

  • How much funding has Tenvie raised over time?

    Tenvie has raised $200M.

  • Who are Tenvie’s investors?

    ARCH Venture Partners, Eight Roads, F-Prime, and Mubadala Capital have invested in Tenvie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process